1 / 1

Successful Treatment of Acquired Angioedema Using B-lymphocyte Depletion Therapy

Successful Treatment of Acquired Angioedema Using B-lymphocyte Depletion Therapy Chang Na, MD, David Podell, MD, Christopher Randolph, David Dreyfus, Denise Kearney. Yale Primary Care Program, Waterbury, CT 1,2 , Allergy, Asthma & Immunology, Waterbury, CT 3,4,5.

eloise
Download Presentation

Successful Treatment of Acquired Angioedema Using B-lymphocyte Depletion Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Successful Treatment of Acquired Angioedema Using B-lymphocyte Depletion Therapy Chang Na, MD, David Podell, MD, Christopher Randolph, David Dreyfus, Denise Kearney. Yale Primary Care Program, Waterbury, CT1,2, Allergy, Asthma & Immunology, Waterbury, CT3,4,5 <?xml version="1.0"?><Settings><answerBulletFormat>Numeric</answerBulletFormat><answerNowAutoInsert>No</answerNowAutoInsert><answerNowStyle>Explosion</answerNowStyle><answerNowText>Answer Now</answerNowText><chartColors>Use PowerPoint Color Scheme</chartColors><chartType>Horizontal</chartType><correctAnswerIndicator>Checkmark</correctAnswerIndicator><countdownAutoInsert>No</countdownAutoInsert><countdownSeconds>10</countdownSeconds><countdownSound>TicToc.wav</countdownSound><countdownStyle>Box</countdownStyle><gridAutoInsert>No</gridAutoInsert><gridFillStyle>Answered</gridFillStyle><gridFillColor>255,255,0</gridFillColor><gridOpacity>50%</gridOpacity><gridTextStyle>Keypad #</gridTextStyle><inputSource>Response Devices</inputSource><multipleResponseDivisor># of Responses</multipleResponseDivisor><participantsLeaderBoard>5</participantsLeaderBoard><percentageDecimalPlaces>0</percentageDecimalPlaces><responseCounterAutoInsert>No</responseCounterAutoInsert><responseCounterStyle>Oval</responseCounterStyle><responseCounterDisplayValue># of Votes Received</responseCounterDisplayValue><insertObjectUsingColor>Red</insertObjectUsingColor><showResults>Yes</showResults><teamColors>Use PowerPoint Color Scheme</teamColors><teamIdentificationType>None</teamIdentificationType><teamScoringType>Voting pads only</teamScoringType><teamScoringDecimalPlaces>1</teamScoringDecimalPlaces><teamIdentificationItem></teamIdentificationItem><teamsLeaderBoard>5</teamsLeaderBoard><teamName1></teamName1><teamName2></teamName2><teamName3></teamName3><teamName4></teamName4><teamName5></teamName5><teamName6></teamName6><teamName7></teamName7><teamName8></teamName8><teamName9></teamName9><teamName10></teamName10><showControlBar>All Slides</showControlBar><defaultCorrectPointValue>0</defaultCorrectPointValue><defaultIncorrectPointValue>0</defaultIncorrectPointValue><chartColor1>187,224,227</chartColor1><chartColor2>51,51,153</chartColor2><chartColor3>0,153,153</chartColor3><chartColor4>153,204,0</chartColor4><chartColor5>128,128,128</chartColor5><chartColor6>0,0,0</chartColor6><chartColor7>0,102,204</chartColor7><chartColor8>204,204,255</chartColor8><chartColor9>255,0,0</chartColor9><chartColor10>255,255,0</chartColor10><teamColor1>187,224,227</teamColor1><teamColor2>51,51,153</teamColor2><teamColor3>0,153,153</teamColor3><teamColor4>153,204,0</teamColor4><teamColor5>128,128,128</teamColor5><teamColor6>0,0,0</teamColor6><teamColor7>0,102,204</teamColor7><teamColor8>204,204,255</teamColor8><teamColor9>255,0,0</teamColor9><teamColor10>255,255,0</teamColor10><displayAnswerImagesDuringVote>Yes</displayAnswerImagesDuringVote><displayAnswerImagesWithResponses>Yes</displayAnswerImagesWithResponses><displayAnswerTextDuringVote>Yes</displayAnswerTextDuringVote><displayAnswerTextWithResponses>Yes</displayAnswerTextWithResponses><questionSlideID></questionSlideID><controlBarState>Expanded</controlBarState><isGridColorKnownColor>True</isGridColorKnownColor><gridColorName>Yellow</gridColorName></Settings> <?xml version="1.0"?><AllResponses /> <?xml version="1.0"?><AllQuestions /> <?xml version="1.0"?><AllAnswers /> Discussion Continued Discussion Case Description Continued  Learning Objectives • Acquired C1-INH deficiency is a rare condition which results in recurrent angioedema. • The condition is characterized by reduced C1-INH level or function, hyperactivation of the classical complement pathway, and bradykinin mediated recurrent angioedema. • Acquired C1-INH deficiency had been reported in association with lymphoproliferative disease (LPD) and autoimmune disorders. • The discovery of an auto-antibody IgG against C1-INH in patients with angioedema demonstrates that an auto-antibody mechanism may cause acquired C1-INH deficiency. • B lymphocytes appear to play a key part in the mechanism of action of acquired angioedema in a variety of autoimmune syndromes. • Identify clinical manifestations of acquired C1 inhibitor (C1-INH) deficiency • Learn about the immunobiology underlying acquired C1-INH deficiency • Make treatment decisions based on mechanism of disease and the latest literature data • Patient B: A 37 year old woman with Crohn’s disease and allergic asthma, presented with angioedema associated with wheezing and urticaria. • Laboratory tests showed elevated IgE levels and positive aeroallergen skin testing. A hematologic evaluation showed no evidence of lymphoma. • Rituximab has been effective as adjunctive treatment of LPD, in particular B-cell lymphomas. Even though there was no associated LPD in our patients, they were successfully treated with B-lymphocyte depletion for acquired angioedema. • Rituximab appears to work by eliminating the clonal B lymphocyte population expressing a clonal Immunoglobulin G binding to C1 INH. • Anti-TNF agents such as adalizumab deplete B lymphocytes via effects on follicular dendritic cells and disruption of germinal center formation and maintenance. • B-lymphocyte depletion with humanized monoclonal antibodies such as rituximab or adalizumab appears to be an effective, long lasting therapy for acquired angioedema associated with a variety of autoimmune syndromes. • Patient C: A 41 year old woman with myasthenia gravis and anti-phospholipids syndrome, presented with angioedema and associated bowel and laryngeal edema requiring intubation. • Laboratory tests showed low C1q, C2, C3, C4 and anti-C1q antibody. Case Description • Patient A: A 38 year old woman presented with seropositive deforming erosive rheumatoid arthritis (RA) and angioedema associated with acquired C1-INH deficiency. • Laboratory tests showed decreased C1q, C3, C4, and Ch50, worsening anemia, and elevated ESR. • She had a normal CT chest/abdomen/pelvis, normal SPEP, and flow cytometry that showed decreased CD4 and CD8 T cells but otherwise normal lymphoid phenotype. Thickened ascending colon Clinical Course Learning Points • After failure of other therapy including etanercept and corticosteroids (A), xolair (B), and kallekrein antagonist and corticosteroids (C), all three patients responded with complete remission of symptoms after B-lymphocyte depletion therapy with rituximab (A, C) or adalizumab (B). • The patients have been symptom free for 5 years, 3 years and 6 months thus far. • C1-INH deficiency is a rare condition resulting in recurrent angioedema episodes. • A lymphoproliferative autoimmune mechanism may cause acquired C1-INH deficiency. • Our cases highlight that B-lymphocyte depletion may be an effective treatment for acquired C1-INH deficiency Advanced rheumatoid arthritis with fusion of the carpal bones (yellow arrow). Metacarpal phalangeal joint subluxation (blue arrow).

More Related